What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the ...

Hims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's ...

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should know. Hims & Hers Health beat analysts’ revenue expectations by 4. ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Shares of Hims & Hers Health Inc ( HIMS -25.79%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...